The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.
Participants with new diagnosis of MM as defined by:
ICD-9-CM: 203.0x and/or ICD-10-CM: C90.0x or C90 during the study period At least two documented clinical visits for MM on different days and occurring on or after January 1, 2011 Participants who received at least one systemic MM therapy on or after initial MM diagnosis Participants who did not receive clinical study drug at any time during the observation period Participants with race information
Exclusion Criteria:
Exclusion Criteria Patients with less than 6 months of medical data during the prior or follow-up period Patients in more than one race category (mix race), missing race, unknown race, and "other" race
Patients diagnosed with the following hematological cancers on or prior to the index date:
Patients with evidence of skin hyperpigmentation (ICD-9: 709.00, 709.09; ICD-10: L81.0, L81.1, L81.4, L81.8) on or prior to the index date
709.00 Dyschromia, unspecified 709.09 Other dyschromia L81.0 Post inflammatory hyperpigmentation L81.1 Chloasma/melasma L81.4 Other melanin hyperpigmentation L81.8 Other specified disorders of pigmentation
